« Zurück
Startseite /
Human SLAMF7/CRACC/CD319 Protein (SMF-HM307)

Human SLAMF7/CRACC/CD319 Protein (SMF-HM307)

ArtNr	SMF-HM307-100UG
Hersteller	KactusBio
Menge	100 ug
Quantity options	100 ug 500 ug
Kategorie	Oncology By Cell Type Hematology Peptides & Proteins Recombinant Proteins Myelom
Typ	Proteins Recombinant
Format	Lyophilized
Specific against	Human (Homo sapiens)
Host	HEK293
Konjugat/Tag	C-mFc
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
Sequence	Ser23-Met226
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	CD2 subset 1,CRACC,Novel Ly9,CD319,SLAMF7,CS1,19A,FOAP-12
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	SLAMF7/CRACC/CD319
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 24 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 48.8 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result.
Description	Recombinant Human SLAMF7/CRACC/CD319 Protein is expressed from HEK293 with mFc (IgG1) tag at the C-Terminus.It contains Ser23-Met226
Background	CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

SMF-HM307-100UG-datasheet.pdf

SMF-HM307-100UG-safety-datasheet.pdf